insulins human
Preclinical
Eli Lillyinsulins human is one of 42 therapeutic programs targeting Type 2 Diabetes. It is currently in Preclinical.
2
Indications
0
Total Trials
0
Active Trials
41
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
NOVOLIN R
Novo NordiskPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Forxiga
AstraZenecaPreclinical
Lovaza
AstraZenecaPreclinical
Sulfonylureas
Eli LillyPreclinical
Acipimox
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for insulins human. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company